As the United States approaches its 250th anniversary, USA TODAY examines the enduring legacy of the companies that shaped the nation's culture, economy, and global identity.
An analysis of the most-held stocks on the Robinhood platform reveals where the retail investing crowd is placing its bets, with two tech giants emerging as particularly compelling long-term investments.
After a prolonged downturn, the pre-owned watch market saw a modest rebound in late 2025, driven largely by Patek Philippe and Rolex. However, a new report reveals a stark divide, with most brands still struggling with value retention as consumers pivot towards pragmatic purchases.
A speculative frenzy fueled by geopolitical tensions and dollar fears met its abrupt end last Friday, triggering the worst single-day plunge in silver since 1980 and a massive gold sell-off. Analysts point to leveraged bets and a shifting Fed outlook as key catalysts for the historic crash.
The so-called 'Super Bowl Indicator' correctly predicted a market rise after last year's NFC win, but a deeper look at the data reveals it's little more than a coin toss—and a cautionary tale about spurious correlations in finance.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Despite a significant lag behind the broader market over the past year, analysts maintain a cautiously optimistic stance on Copart's long-term prospects, even as near-term headwinds persist.
Recent financial disclosures reveal significant repositioning by Speaker Emerita Nancy Pelosi and her husband in tech giants Nvidia, Apple, and Alphabet, sparking investor interest in their strategy of locking in gains while maintaining bullish exposure.
The FIRE movement is no longer the exclusive domain of high-flying tech salaries. A growing community of middle and working-class Americans is proving that strategic frugality and disciplined investing can pave the way to financial independence decades ahead of schedule.
Internal correspondence reveals Coinbase co-founder Fred Ehrsam was personally briefed on and facilitated a multi-million dollar investment from the convicted sex offender, arranged by Tether's Brock Pierce.
As the U.S. renewable energy sector builds on a record-breaking 2025, it faces a critical juncture defined by supply chain pressures, extreme weather, and evolving market rules. Strategic adaptation, not just growth, will determine its sustainable trajectory.
Union Pacific is preparing a revised application for its proposed $85 billion merger with Norfolk Southern after regulators rejected the initial filing over competition and information concerns. The deal, which would create the first coast-to-coast freight railroad in the U.S., faces intense scrutiny over its potential impact on shipping costs, labor, and market competition.
Palantir Technologies prepares to report Q4 2025 earnings after the bell, with Wall Street eyeing $1.33 billion in revenue and $0.23 EPS. The stock's recent 17.5% slump underscores investor anxiety over its premium valuation and the sustainability of its explosive commercial growth.
As sports betting handles hit record highs, data reveals a stark contrast: the average bettor consistently loses, while disciplined investing in instruments like index funds builds wealth over time.
As Bob Iger prepares for his second departure, the Disney CEO outlines a forward-looking mandate for his successor during an earnings call, emphasizing evolution in a dynamic media landscape.
Stephens lowers price target on Cal-Maine Foods (CALM) citing near-term oversupply pressures, but the egg producer's long-term strategy remains focused on expanding its cage-free capacity through acquisition.
With the FIFA World Cup in North America, the Milano Cortina Winter Olympics, and a packed calendar of major events, 2026 is poised to be a landmark year for sports. Brands and retailers are deploying sophisticated strategies that prioritize cultural marketing and community engagement over mere sales spikes, navigating a landscape where consumer loyalty is won through storytelling, not just sponsorship.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
